Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Sponsor: National Cancer Institute (NCI)
This observational or N/A phase trial investigates Advanced Malignant Solid Neoplasm and Recurrent Childhood Ependymoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 85 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with erdafitinib with advanced solid tumors (including central nervous system \[CNS\] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway. SECONDARY OBJECTIVES: I. To estimate the progression free survival in pediatric patients treated with erdafitinib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4. II. To obtain information about the tolerability of erdafitinib in children with relapsed or refractory cancer. III. To provide preliminary estimates of the pharmacokinetics of erdafitinib in children with relapsed or refractory cancer. EXPLORATORY OBJECTIVE: I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA). OUTLINE: Patients receive erdafitinib orally (PO) once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy...
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with erdafitinib with advanced solid tumors (including central nervous system \[CNS\] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with erdafitinib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4.
II. To obtain information about the tolerability of erdafitinib in children with relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of erdafitinib in children with relapsed or refractory cancer.
EXPLORATORY OBJECTIVE:
I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive erdafitinib orally (PO) once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
After completion of study treatment, patients are followed up periodically.
Status Flow
Change History
85 versions recorded-
Apr 23, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE2
-
Jan 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 80 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
May 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Apr 2023 — May 2023 [monthly]
Suspended PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Suspended PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Suspended PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Suspended PHASE2
-
Nov 2022 — Jan 2023 [monthly]
Suspended PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Suspended PHASE2
-
May 2022 — Jun 2022 [monthly]
Suspended PHASE2
-
Apr 2022 — May 2022 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .